Skip to main content

Advertisement

SpringerLink
Log in

Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab

  • Case Reports
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy. Two years later C-erbB2-positive IBC was diagnosed in the right breast, and was treated with mastectomy and radiotherapy. Two years later skin metastases appeared, and trastuzumab was started initially as monotherapy, and later with paclitaxel and capecitabine. More than 12 years after diagnosis and 7 years after trastuzumab was started, the patient remains in complete clinical remission on trastuzumab and capecitabine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chang S, Parker SL, Pham T et al (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology and end results program of the National Cancer Institute, 1975–1992. Cancer 82:2366–2372

    Article  PubMed  CAS  Google Scholar 

  2. Kleer CG, van Golen KL, Merajver SD (2000) Molecular biology of breast cancer metastasis: inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2:423–429

    Article  PubMed  CAS  Google Scholar 

  3. Palangie T, Mosseri V, Mihura J et al (1994) Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 7:921–927

    Article  Google Scholar 

  4. Hoffmeyer S, Burk O, von Richter O et al (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478

    Article  PubMed  CAS  Google Scholar 

  5. Carrick S, Ghersi D, Wilcken N et al (2004) Platinum containing regimens for metastatic breast cancer. Cochrane Database System Rev (2): CD003374

  6. Konecny GE, Pegram MD (2004) Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology (Williston Park) 18[14 Suppl 12]: 32–36

    Google Scholar 

  7. Crown J, Pegram M (2003) Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy. Breast Cancer Res Treat 79[Suppl 1]:S11–18

    Article  PubMed  CAS  Google Scholar 

  8. Martin M (2001) Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2:190–208; discussion 209

    Article  PubMed  CAS  Google Scholar 

  9. Vogel C, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single-agent in first line treatment of Her2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Article  PubMed  CAS  Google Scholar 

  10. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  PubMed  CAS  Google Scholar 

  11. Schaller G, Fuchs I, Gonsch T et al (2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25:3246–3250

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Farmacia Hospitalaria, Hospital Universitario de Guadalajara, ES-19002, Guadalajara, Spain

    Alicia Lázaro, Almudena Amorós & Miriam Heredia

  2. Sección de Oncología Médica, Hospital Universitario de Guadalajara, C/ Donantes de Sangre, s/n, ES-19002, Guadalajara, Spain

    Javier Cassinello & Ana López-Alfonso

Authors
  1. Alicia Lázaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Cassinello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Almudena Amorós
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Miriam Heredia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ana López-Alfonso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Cassinello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lázaro, A., Cassinello, J., Amorós, A. et al. Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab. Clin Transl Oncol 10, 587–590 (2008). https://doi.org/10.1007/s12094-008-0255-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-008-0255-6

Keywords

Search

Navigation